GSK 4184258A
Alternative Names: GSK-4184258ALatest Information Update: 28 Jun 2024
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in United Kingdom (Parenteral)
- 05 May 2021 Phase-I clinical trials in COVID-2019 infections (Prevention) in United Kingdom (Parenteral) (GlaxoSmithKline pipeline, May 2021)
- 05 May 2021 Preclinical trials in COVID-2019 infections (Prevention) in United Kingdom (Parenteral) before May 2021 (GlaxoSmithKline pipeline, May 2021)